Patents by Inventor Michael Regnier

Michael Regnier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250145957
    Abstract: Provided herein are compositions and methods directed toward the discovery of improved methods for generating deoxyATP (dATP) in cells that can be delivered to a graft site in the heart to enhance cardiac function.
    Type: Application
    Filed: August 16, 2024
    Publication date: May 8, 2025
    Applicant: UNIVERSITY OF WASHINGTON
    Inventors: Michael REGNIER, Charles E. MURRY, Stephen D. HAUSCHKA
  • Publication number: 20250121038
    Abstract: Provided herein are isolated nucleic acids that encode a stable form of Rrm2 for the use of increasing the intracellular Rrm2 protein levels and cytosolic 2-deoxy-ATP (dATP) levels. Further provided herein are methods for treating a cardiac disease or disorder, e.g., myocardial infarction or myocardial ischemia, by administering the isolated nucleic acids, a polypeptide encoded by the isolated nucleic acids, or composition comprising the isolated nucleic acids to a subject in need thereof.
    Type: Application
    Filed: December 16, 2024
    Publication date: April 17, 2025
    Applicant: UNIVERSITY OF WASHINGTON
    Inventors: Michael REGNIER, Charles E. MURRY, Xuan GUAN
  • Patent number: 12208133
    Abstract: Provided herein are isolated nucleic acids that encode a stable form of Rrm2 for the use of increasing the intracellular Rrm2 protein levels and cytosolic 2-deoxy-ATP (dATP) levels. Further provided herein are methods for treating a cardiac disease or disorder, e.g., myocardial infarction or myocardial ischemia, by administering the isolated nucleic acids, a polypeptide encoded by the isolated nucleic acids, or composition comprising the isolated nucleic acids to a subject in need thereof.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: January 28, 2025
    Assignee: UNIVERSITY OF WASHINGTON
    Inventors: Michael Regnier, Charles E. Murry, Xuan Guan
  • Publication number: 20240189481
    Abstract: Described herein are compositions and methods relating to the improvement of cardiac function. Various embodiments relate to transplant compositions comprising cardiomyocytes which are engineered to be non-contractile, and to methods of using such cardiomyocytes or transplant compositions to improve cardiac function, e.g., by administering them to cardiac tissue.
    Type: Application
    Filed: April 6, 2022
    Publication date: June 13, 2024
    Applicant: UNIVERSITY OF WASHINGTON
    Inventors: Charles E. MURRY, Michael REGNIER, Hans REINECKE, Xiulan YANG, Dasom YOO
  • Publication number: 20200405824
    Abstract: The present disclosure relates generally to methods of treating a subject having muscular dystrophy or DMD. The present disclosure also relates generally to methods of prophylactically treating a subject at risk of developing muscular dystrophy or DMD. In some embodiments, the methods may include administering a pharmaceutical composition including an RRM1 gene, an RRM2 gene, and a delivery vehicle to a subject. In another embodiment, the methods may include administering a pharmaceutical composition including an RRM1 gene and an RRM2 gene coupled to a regulatory cassette to a subject. In yet another embodiment, the methods may include administering a pharmaceutical composition including an RRM 1 gene, an RRM2 gene, a regulatory cassette, and a delivery vehicle to a subject.
    Type: Application
    Filed: June 26, 2020
    Publication date: December 31, 2020
    Applicant: UNIVERSITY OF WASHINGTON
    Inventors: Guy L. ODOM, Michael REGNIER, Jeffrey S. CHAMBERLAIN, Stephen D. HAUSCHKA
  • Publication number: 20200000886
    Abstract: Provided herein are isolated nucleic acids that encode a stable form of Rrm2 for the use of increasing the intracellular Rrm2 protein levels and cytosolic 2-deoxy-ATP (dATP) levels. Further provided herein are methods for treating a cardiac disease or disorder, e.g., myocardial infarction or myocardial ischemia, by administering the isolated nucleic acids, a polypeptide encoded by the isolated nucleic acids, or composition comprising the isolated nucleic acids to a subject in need thereof.
    Type: Application
    Filed: June 28, 2019
    Publication date: January 2, 2020
    Applicant: UNIVERSITY OF WASHINGTON
    Inventors: Michael REGNIER, Charles E. MURRY, Xuan GUAN
  • Patent number: 9868937
    Abstract: Compositions and methods for improving cardiac function, myocardial contractility and relaxation in a mammal are provided. Cardiomyocytes transfected with one or more expression vectors comprising a ribonucleotide reductase subunit R1-encoding nucleic acid sequence and a ribonucleotide reductase subunit R2-encoding nucleic acid sequence operably linked to a promoter are grafted to a mammalian myocardium. Also provided are compositions and methods for delivering dATP to a myocardium through grafting of donor cells overexpressing R1 and R2. dATP is thereby produced in situ and delivered through gap junctions established between donor cells and host cardiomyocytes. Alternatively, viral vector(s) having the R1 and R2-encoding construct(s) are administered to the mammal directly. Improvement of cardiac function can also be effected by administration of vectors comprising a nucleic acid sequence encoding a L48Q, 61 Q, or L57Q cTnC variant.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: January 16, 2018
    Assignee: University of Washington
    Inventors: Michael Regnier, Michael Laflamme, Charles Murry, F. Steven Korte, Scott Lundy, Stephen Denison Hauschka, Jeffrey S. Chamberlain, Guy Odom
  • Publication number: 20160186139
    Abstract: Compositions and methods for improving cardiac function, myocardial contractility and relaxation in a mammal are provided. Cardiomyocytes transfected with one or more expression vectors comprising a ribonucleotide reductase subunit R1-encoding nucleic acid sequence and a ribonucleotide reductase subunit R2-encoding nucleic acid sequence operably linked to a promoter are grafted to a mammalian myocardium. Also provided are compositions and methods for delivering dATP to a myocardium through grafting of donor cells overexpressing R1 and R2. dATP is thereby produced in situ and delivered through gap junctions established between donor cells and host cardiomyocytes. Alternatively, viral vector(s) having the R1 and R2-encoding construct(s) are administered to the mammal directly. Improvement of cardiac function can also be effected by administration of vectors comprising a nucleic acid sequence encoding a L48Q, 61 Q, or L57Q cTnC variant.
    Type: Application
    Filed: May 29, 2012
    Publication date: June 30, 2016
    Applicant: University of Washington
    Inventors: Michael Regnier, Michael Laflamme, Charles Murry, F. Steven Korte, Scott Lundy, Stephen Denison Hauschka, Jeffrey S. Chamberlain